Abstract
Progress in the prevention of stroke in patients with atrial fibrillation (AF) dominated advances in the area of cerebrovascular disorders in 2009. The most significant advance was the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study,1 which compared warfarin with a new oral antithrombin, dabigatran, in patients with AF. Vitamin K antagonists, such as warfarin, are the most effective drugs available for protection against stroke in patients with AF who are at increased stroke risk.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
